Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Leases (2016 - 2018)

Sangamo Therapeutics (SGMO) has disclosed Capital Leases for 3 consecutive years, with $27.7 million as the latest value for Q4 2018.

  • For Q4 2018, Capital Leases rose 11.93% year-over-year to $27.7 million; the TTM value through Dec 2018 reached $27.7 million, up 11.93%, while the annual FY2018 figure was $27.7 million, 11.93% up from the prior year.
  • Capital Leases hit $27.7 million in Q4 2018 for Sangamo Therapeutics, up from $26.9 million in the prior quarter.
  • Across five years, Capital Leases topped out at $27.7 million in Q4 2018 and bottomed at $213000.0 in Q1 2016.
  • Average Capital Leases over 3 years is $12.4 million, with a median of $3.9 million recorded in 2016.
  • Year-over-year, Capital Leases skyrocketed 1744.13% in 2017 and then grew 11.93% in 2018.
  • Sangamo Therapeutics' Capital Leases stood at $3.9 million in 2016, then soared by 527.07% to $24.7 million in 2017, then rose by 11.93% to $27.7 million in 2018.
  • According to Business Quant data, Capital Leases over the past three periods came in at $27.7 million, $26.9 million, and $26.2 million for Q4 2018, Q3 2018, and Q2 2018 respectively.